Discussion: HBV mutation rtA181T/V and rtN236T could lead to drug resistance of ADV, and the influence of HBV genotypes on the resistance to ADV has not been clarified.
Discussion: It was noteworthy that ADV-associated mutation rtA181T was considered as a cross-resistant mutation, which could induce resistance to LMV and LdT in patients never exposed to these antiviral drugs.
Discussion: Patients infected with genotype C had a higher rate of mutant
Discussion: analyzed HBV sequences from 1236 CHB patients and found significantly higher frequency of rtA181T in HBV genotypes C isolates compared to genotypes D and A isolates (63.8% vs.
Drug-resistance associated mutations in polymerase (p) gene of hepatitis B virus isolated from malaysian HBV carriers.
Abstract: A number of significant drug resistant mutations were found in five patients including S202I, N236T, M250L, L180M/V, M204I, A181T, T184G, M250V, and V173L.
Result: Based on genome analysis, Patient 155693 possessed mutation A181T, which was responsi
Discussion: The mutations found in the four patients were L180M/V, M204I, A181T, and V173L.Among these, L180M/V and M204I were frequently observed.
Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Abstract: A series of mutant clones containing rtA181T and/or rtI233V mutations were constructed and determined the effect of these mutations on the replication ability and drug resistance.
Abstract: Among drug-resistant mutations, the single rtA181T mutation is known to confer cross-resistance to antiviral drugs.
Abstract: An in vitro study revealed that the effect of the rtA181T mutation on viral replication and drug resistance is dependent on the mutations in the overlapping surface gene.
Abstract: Compared to the rtA181T surface missense mutation
Mutation profiling of the hepatitis B virus strains circulating in North Indian population.
Discussion: rtN236T a primary mutation in the D domain, rtA181T/V at the B domain and rtQ215S at the C-D inter-domain have been associated with Adefovir and Lamivudine resistance were also observed in 8 cases.
Lamivudine and Adefovir Motif Variants Detected in chronic Hepatitis B patients.
Abstract: This mutations; responsible for lamivudine resistance YMDD+YVDD (n=10), YMDD+YIDD (n=12), YIDD (n=2), YVDD (=1); responsible for adefovir resistance N236T (n=3), A181T (n=5); responsible for lamivudine and adefovir resistance YMDD+YIDD+N236T (n=1).
Rapid detection of hepatitis B virus variants associated with lamivudine and adefovir resistance by multiplex ligation-dependent probe amplification combined with real-time PCR.
PMID: 24478474
2014
Journal of clinical microbiology
Abstract: Based on the results of MLP-RT-PCR, the mutations rtM204V, rtM204I, rtA181T, rtA181V, and rtN236T were 95.7% (111/116 patients), 98.3% (114/116 patients), 99.1% (115/116 patients), 98.3% (114/116 patients), and 99.1% (115/116 patients) concordant, respectively, with those of direct sequencing.
Abstract: For this study, a multiplex ligation-dependent probe real-time PCR (MLP-RT-PCR) method was developed to simultaneously detect lamivudine (LAM)- and adefovir (ADV)-resistant HBV mutants (those with the mutations rtM204V/I, rt
HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D.
Abstract: CONCLUSIONS: Genotype B, C and D isolates with single ADV resistance mutations remained fully sensitive to TFV, while the double mutants rtA181T+rtN236T and rtA181V+rtN236T exhibited either no change or low-level reduced susceptibility to TFV across genotypes.
Abstract: Clinical isolates containing the rtA181T+rtN236T double mutant remained sensitive to TFV in genotype D but exhibited reduced susceptibility to TFV in genotypes B and C.
Abstract: METHODS: Full-length HBV isolates from patients infected with genotype B, C and D virus had
Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.
Abstract: These viral variants were detected mostly at low frequencies (0.63-5.92%) at EOT, but one LMV-treated mother had an rtA181T variant that increased from 2.2% pretherapy to 25.59% at EOT.
Abstract: UDPS showed that LMV therapy resulted in increased viral quasispecies diversity and positive selection of HBV variants with reverse transcriptase amino acid substitutions at sites associated with primary LMV resistance (rtM204I/V and rtA181T) in four (19%) women.
rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus.
HBV mutation literature information.
PMID: 
2015
Scientific reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT